Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma

NCT07356245 is registered in ClinicalTrials.gov with Jonathan Brammer as lead sponsor.

NCT NCT07356245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07356245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma
Lead sponsor
Jonathan Brammer
Phase
Phase 2
Overall status
Recruiting
Start date
February 12, 2026
Completion date
January 31, 2027
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult t-cell leukemia/lymphoma, cutaneous t cell lymphoma, graft versus host disease, lymphoma, t-cell, peripheral t cell lymphoma, primary cutaneous t-cell non-hodgkin lymphoma, t-cell lymphoma, t-cell prolymphocytic leukemia